Prevalence of Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) in Methamphetamine Dependence: A Descriptive Study

Farnia, Vahid; Mousavi, Seyyed Bagher; Tatari, Faezeh; Salemi, Safora; Golshani, Sanobar; Alikhani, Mostafa; Heydari, Shima; Hookari, Sara

doi:10.5812/ijpbs.61329

Cited by 7 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference may account for some of our observations. For example, a study found a 30% prevalence of childhood attention-deficit/hyperactivity disorder in methamphetamine users, 45 which might indicate that a subpopulation with more hyperactivity traits such as restlessness could have yielded more conclusive results in the present study, as well as for other outcomes.…”

Section: Discussionmentioning

confidence: 73%

Infralow neurofeedback in the treatment of substance use disorders: a randomized controlled trial

Gabrielsen

Clausen

Haugland

et al. 2022

jpn

View full text Add to dashboard Cite

Background: Infralow neurofeedback (ILF-NF) was recently developed as a subtype of traditional, frequency-based neurofeedback that targets cerebral rhythmic activity below 0.5 Hz and improves brain self-regulation. The efficacy of ILF-NF in the treatment of substance use disorder has not yet been evaluated, but clinical evidence suggests that it may prevent relapse by improving functioning in various life domains. The current study aimed to fill this research gap and extend empirical evidence related to this issue. Methods: Ninety-three patients with substance use disorders at an outpatient unit in Norway were randomized to receive 20 sessions (30 minutes each) of ILF-NF training combined with treatment as usual (TAU), or TAU alone. The primary outcome was quality of life post-treatment as an overall measure of functioning. We analyzed between-group differences using Student t tests. Results: We found no significant differences in quality of life between groups. We found similar nonsignificant results for most of the secondary outcome measures, including drug use, sleep, anxiety and depression. Compared to TAU, the ILF-NF + TAU group reported significantly lower restlessness scores post-treatment (mean difference −1.8, 95 % confidence interval -3.1 to -0.5; p = 0.006). Limitations: This study was limited by broad inclusion criteria and a lack of placebo control (sham neurofeedback treatment). Conclusion: ILF-NF offered limited additional benefit when combined with TAU, except in the area of restlessness. Future studies could further investigate the relationship between ILF-NF, restlessness and substance use in targeted subpopulations to illuminate relapse mechanisms. Clinical trial registration: ClinicalTrials.gov: NCT03356210

show abstract

Section: Discussionmentioning

confidence: 73%

Infralow neurofeedback in the treatment of substance use disorders: a randomized controlled trial

Gabrielsen

Clausen

Haugland

et al. 2022

jpn

View full text Add to dashboard Cite

show abstract

“…This could result in people being treated for ADHD being included in the study cohort. To minimise ascertainment bias, we excluded individuals diagnosed with or being treated for ADHD, but because of strong links between ADHD, mental health issues and substance use,65 66 we will conduct a sensitivity analysis to determine whether this exclusion significantly impacts our findings. A second limitation is that only people interacting with the health system following methamphetamine use will be included in the study.…”

Section: Methods and Analysismentioning

confidence: 99%

Characterising methamphetamine use to inform health and social policies in Manitoba, Canada: a protocol for a retrospective cohort study using linked administrative data

et al. 2022

View full text Add to dashboard Cite

IntroductionRising use of methamphetamine is causing significant public health concern in Canada. The biological and behavioural effects of methamphetamine range from wakefulness, vigour and euphoria to adverse physical health outcomes like myocardial infarction, haemorrhagic stroke, arrhythmia and seizure. It can also cause severe psychological complications such as psychosis. National survey data point to increasing rates of methamphetamine use, as well as increasing ease of access and serious methamphetamine-related harms. There is an urgent need for evidence to address knowledge gaps, provide direction to harm reduction and treatment efforts and inform health and social policies for people using methamphetamine. This protocol describes a study that aims to address this need for evidence.MethodsThe study will use linked, whole population, de-identified administrative data from the Manitoba Population Research Data Repository. The cohort will include individuals in the city of Winnipeg, Manitoba, who came into contact with the health system for reasons related to methamphetamine use from 2013 to 2021 and a comparison group matched on age, sex and geography. We will describe the cohort’s sociodemographic characteristics, calculate incidence and prevalence of mental disorders associated with methamphetamine use and examine rates of health and social service use. We will evaluate the use of olanzapine pharmacotherapy in reducing adverse emergency department outcomes. In partnership with Indigenous co-investigators, outcomes will be stratified by First Nations and Métis identity.Ethics and disseminationThe study was approved by the University of Manitoba Health Research Ethics Board, and access datasets have been granted by all data providers. We also received approval from the First Nations Health and Social Secretariat of Manitoba’s Health Information Research Governance Committee and the Manitoba Métis Federation. Dissemination will be guided by an ‘Evidence 2 Action’ group of public rightsholders, service providers and knowledge users who will ensure that the analyses address the critical issues.

show abstract

“…Methamphetamine increases the body metabolism and creates a state of vitality, increases consciousness and gives the user a sense of increased energy. 3 It is highly addictive and causes more damage to the person than other amphetamines. 3,4 The evidence shows that experiencing negative emotions and avoiding negative emotional states as well as distress tolerance are related to incompatibility, 5 antisocial behaviors, 6 anxiety issues, 7 and tendency to abuse alcohol and drugs.…”

Section: Introductionmentioning

confidence: 99%

“…3 It is highly addictive and causes more damage to the person than other amphetamines. 3,4 The evidence shows that experiencing negative emotions and avoiding negative emotional states as well as distress tolerance are related to incompatibility, 5 antisocial behaviors, 6 anxiety issues, 7 and tendency to abuse alcohol and drugs. [8][9][10] Distress tolerance is defined as the individual's capability to experience and tolerate negative emotional states.…”

Section: Introductionmentioning

confidence: 99%

“…10 Kaiser et al evaluated 522 college students and realized that negative emotions and distress tolerance could be good predictors for drug abuse. 1 Since opioids are drugs that reduce the ability to respond to stimuli by slowing down the activities of the central nervous system and physical senses, 15,16 and methamphetamines increase alertness and general arousal and have a different function than that of the opioids, 3,17 and these two groups of drugs have different psychological impacts, in this study, these two groups of drugs were compared together and to the general population. Moreover, while distress tolerance is a basic factor in the etiology of drug dependence, and some studies have considered this variable, few studies have compared distress tolerance and its subscales in dependence to various drugs and have compared this variable between addicts and non-abuser.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Distress tolerance in methamphetamine and opium abusers with non-drug abuser (A comparative analysis)

Shakeri

Farnia

Davarinejad

et al. 2020

Clinical Epidemiology and Global Health

Self Cite

View full text Add to dashboard Cite

Evidence suggests that the way of enduring emotional distress plays a role in the tendency of people to abuse drugs. Accordingly, the present study aims to compare the distress tolerance in metamphetamines and drug abusers with non-drug abusers. Methodology: The current study is an analytical study. The statistical population includes all the patients abusing methamphetamine and opium as well as non-drug abuser individuals visiting Farabi Hospital of Kermanshah in western Iran in 2018. Among the population, 202 individuals (50 individuals abusing methamphetamine, 52 individuals abusing opium, and 100 non-addicted individuals) were selected using convenient sampling, and then they were approximately matched based on demographic variables. The data were collected using the Distress Tolerance Scale developed by Simons and Gaher and were analyzed using multi-variate analysis of variance (MANOVA) and one-way analysis of variance in SPSS20 statistical software application. Results: The finding analysis showed that the score of the concept of absorption by negative emotions (The subscale of distress tolerance) was significantly different between non-drug abusers and methamphetamine abusers (P < 0.05). The mean scores of distress mental evaluation and the overall score of emotional distress tolerance were also statistically significant between non-drug abusers and methamphetamine abusers as well as non-drug abusers and opium abusers. However, this difference was not significant between methamphetamine abusers and opioid abusers (P > 0.05). Conclusion:The findings of the current study show that patients abusing opium and methamphetamine are less capable of tolerating distress compared to non-drug abuser.

show abstract

Prevalence of Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) in Methamphetamine Dependence: A Descriptive Study

Cited by 7 publications

References 27 publications

Infralow neurofeedback in the treatment of substance use disorders: a randomized controlled trial

Infralow neurofeedback in the treatment of substance use disorders: a randomized controlled trial

Characterising methamphetamine use to inform health and social policies in Manitoba, Canada: a protocol for a retrospective cohort study using linked administrative data

Distress tolerance in methamphetamine and opium abusers with non-drug abuser (A comparative analysis)

Contact Info

Product

Resources

About